Product Reports Resources Pricing Login Book a demo

Assertio

Biotech & Life Sciences · Newark, United States · Founded 1995 · IPO 1997

A leading commercial pharmaceutical company bringing differentiated products to patients MoreLess

Assertio Holdings, Inc. is a prominent commercial pharmaceutical company specializing in the development and distribution of branded prescription products. The company focuses on three primary therapeutic areas: neurology, hospital care, and pain and inflammation. Assertio serves a diverse range of clients, including healthcare providers, hospitals, and patients who require specialized medications for chronic and acute conditions. Operating within the pharmaceutical market, Assertio leverages business development strategies such as licensing, mergers, and acquisitions to expand its product portfolio and market reach. The business model is centered around the commercialization of differentiated pharmaceutical products, ensuring compliance with legal and regulatory standards while maintaining high ethical standards. Revenue is generated through the sale of prescription medications, supported by strategic partnerships and a commitment to innovation in therapeutic solutions.

Keywords: pharmaceutical, neurology, hospital care, pain management, prescription products, licensing, mergers, acquisitions, chronic conditions, ethical standards.

Valuation $120M
Revenue $119M
EBITDA $15M
Total funding $50–100M

Talent graph

Assertio's talent

Book a demo to see the people
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

5 investors on Assertio's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series B+ 5 investors entered at this stage
Thomas Weisel Partners
RBC Capital Markets
Morgan Stanley
Pharmakon Holdings
Deerfield

Global footprint

Where Assertio has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
4.7K monthly visits
across markets
🇺🇸 United States66%
🇮🇳 India12.8%
Top 2 markets shown

Patent intelligence

Assertio’s patent portfolio

Estimated portfolio value
$70M

27 active families in the valuation dataset.

Source: Dealroom Patent Intelligence · PatSnap. Portfolio estimates and the family records below have different coverage.

Compare patent portfolios across companies →

Market sentiment

What the market is saying about Assertio

An AI-synthesized read of the highest-engagement posts about Assertio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Assertio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.